Observational Study of Treated and Untreated Acute and Early HIV-1 Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Group A: Long-term follow-up is needed for subjects identified as acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with highly active anti-retroviral therapy (HAART).
Group B: This protocol will also be offered to subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment (Group B)
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Antiretroviral therapy |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Observational Study of Treated and Untreated Acute and Early HIV-1 Infection |
- Development of AIDS or AIDS-defining conditions as per the CDC [ Time Frame: end of study ] [ Designated as safety issue: No ]
- Death due to AIDS or AIDS-defining conditions [ Time Frame: end of study ] [ Designated as safety issue: No ]
- Morbidity due to therapy [ Time Frame: end of study ] [ Designated as safety issue: No ]
- Death due to therapy [ Time Frame: end of study ] [ Designated as safety issue: No ]
- HIV-1 RNA levels [ Time Frame: duration of the study ] [ Designated as safety issue: No ]
- T-cell subsets [ Time Frame: duration of study ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS
| Enrollment: | 399 |
| Study Start Date: | February 2002 |
| Study Completion Date: | November 2010 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Group A
acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
|
Drug: Antiretroviral therapy
HAART therapy
|
|
Group B
subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
|
Drug: Antiretroviral therapy
HAART therapy
|
Detailed Description:
At the initial visit: subjects will undergo a complete history and physical examination. They will have blood drawn for HIV-1 antibody testing, resistance testing, and lymphocyte subsets. In addition, blood will be drawn for hematology, chemistries, and syphilis, and Hepatitis B and C serologies.
Individuals in Group B will not have HIV-1 antibody testing, resistance testing, or Hepatitis B and C serologies performed, as these would have been performed as part of their current protocol. Individuals electing to initiate antiretroviral therapy will obtain standard HAART as prescribed by their physicians.
Group A subjects will be seen at Weeks 4, and 12 ,then every 12 weeks until week 48, then every 24 weeks until week 96. If treated during acute and early infection, then they will be seen every 48 weeks thereafter for 5 years. If untreated during acute and early infection, then they will be discontinued from the study.
Group B participants who have been followed for less than 96 weeks will be seen every 12 weeks until week 48, then every 24 weeks until week 96.
Participants currently enrolled beyond week 96 who were treated during acute and early infection, and whose treatment was uninterrupted, will be seen every 48 weeks. If participants were not treated during acute and early infection, or treatment was interrupted, then they will be discontinued from the study.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects will be recruited from the community or from existing ADARC clinical trials. Participants will give written informed consent.
Inclusion Criteria:
Group A: HIV-1 infected individuals at least 16 years of age with HIV-1 RNA detectable in the blood (>2000 copies/ml) and one of the following:
- a negative test for HIV-1 antibodies
- an indeterminate test for HIV-1 antibodies
- a positive test for HIV-1 antibodies with an immature Western Blot (less than 5 bands) which subsequently matures (addition of 2 or more bands)
- a positive test for HIV-1 antibodies and a documented negative test within 6 months of presentation
- a positive test for HIV-1 antibodies with a simultaneous negative low sensitivity ("detuned") assay (S/C <15)
- Individuals must be able and willing to provide written informed consent
Group B: Approximately 90 individuals diagnosed with acute HIV-1 infection in the past who have been participating in an ADARC/Rockefeller University Hospital protocol involving treatment of acute HIV-1 infection and are currently on that regimen with HIV-1 RNA consistently less than 50 copies/ml and are interested in changing to a protease inhibitor-sparing regimen or may continue to be treated with medications provided or taken as part of a completed ADARC/RUH study of the treatment of acute and early HIV infection
Exclusion Criteria:
- Individuals less than 16 years of age
- Individuals who are unable or unwilling to provide written informed consent
Contacts and Locations| United States, New York | |
| Rockefeller University Hospital | |
| New York, New York, United States, 10065 | |
| Principal Investigator: | Martin Markowitz, MD | Rockefeller University |
More Information
Additional Information:
No publications provided
| Responsible Party: | Rockefeller University |
| ClinicalTrials.gov Identifier: | NCT00219934 History of Changes |
| Other Study ID Numbers: | MMA 0465 |
| Study First Received: | September 20, 2005 |
| Last Updated: | February 15, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Rockefeller University:
|
New HIV Infection Acute HIV Infection Primary HIV Infection Acute Seroconversion Syndrome |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 21, 2013